You are here:

rilpivirine 25mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg tablet (Eviplera®)

Advice

following a full submission:

rilpivirine, emtricitabine, tenofovir disoproxil fumarate tablet (Eviplera®) is accepted for use within NHS Scotland.

Indication under review: treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load ≤100,000 HIV-1 RNA copies/mL.  As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera®.

Rilpivirine, emtricitabine, tenofovir (Eviplera®) maintained virological suppression in patients switched from other antiretroviral regimens.  There is no evidence of efficacy in patients switching from other antiretroviral regimens due to virological failure.

SMC issued advice in February 2012 regarding the use of Eviplera® in antiretroviral treatment-naive adult patients. The current advice extends use to antiretroviral treatment-experienced patients.
 

Drug Details

Drug Name: rilpivirine 25mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg tablet (Eviplera®)
SMC Drug ID: 951/14
Manufacturer: Gilead Sciences Ltd
Indication: Treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load ≤100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera®.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 April 2014

Back